We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Country lags far behind UK and US while jab strategy and technology underpinning it draw fierce criticism
New data bring about policy shift as other EU countries likely to abandon age limits
News about P.1 variant balanced by data confirming vaccines highly effective at preventing disease
Similar move expected in France as EU governments come under pressure to clear stockpile of unused vaccines
Emmanuel Macron forced to extol its virtues after efficacy doubts and adverse publicity damped trust
Von der Leyen confident bloc will hit goal of offering shots to 70% of adult population by end of summer
Pricing undermines Moscow’s claim that it is supplying poor countries with cheaper vaccines
African officials complain of delay in delivery to other member states
Research provides scientific support for government’s road map out of lockdown
GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology
Pharma group behind coronavirus jab plans higher future potential payouts for Soriot
Decision to halt AstraZeneca roll-out highlights vital role played by country’s experts
FT science editor Clive Cookson and US pharma correspondent Hannah Kuchler answer your questions
Conflicting advice about Covid vaccine’s efficacy against variant has bred uncertainty
Pharma group hopes to cut time needed to reach production at scale to 6-9 months
Microsoft approached Pinterest, Carson Block on GameStop
The spread of new Covid strains has made it even more urgent to launch rapid vaccination programmes in poorer countries
Agreement with IDT Biologika will boost capacity and help Europe’s supply shortages
Expert panel advises extending time between doses to between 8 and 12 weeks to improve efficacy
Jeremy Farrar says further virus mutations that reduce jab efficacy should be expected
Concerns over AstraZeneca efficacy against mutation prompt about-turn with global repercussions
UK prime minister insists jab effective in preventing death and serious illness from new variants
E484K, the genetic change in the variant first identified in South Africa, is affecting the efficacy of some vaccines
South Africa halts introduction of jab and Portugal imposes restrictions on use for over-65s
Global vaccines drive is a vital element of the complex path out of the pandemic
International Edition
